BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Midena, E.
Right arrow Articles by Boccato, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Midena, E.
Right arrow Articles by Boccato, P.
Br J Ophthalmol 2000;84:268-272 ( March )

Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil

Edoardo Midena, Claudia Degli Angeli, Massimo Valenti, Valentina de Belvis, Paolo Boccato

Ocular Oncology Service, Institute of Ophthalmology, University of Padua, Padua, Italy

Correspondence to: Edoardo Midena, MD, Ocular Oncology Service, Institute of Ophthalmology, University of Padova, Via Giustiniani 2, 35100 Padova, Italy

Accepted for publication 22 September 1999

AIM---To evaluate the efficacy of topical 5-fluorouracil (5-FU) alone, without concurrent surgery or radiotherapy, for the treatment of conjunctival squamous cell carcinoma.
METHODS---Eight patients affected by conjunctival squamous cell carcinoma (three recurrent cases, three incompletely excised, and two untreated cases) were treated with 1% 5-FU eye drops. Topical 1% 5-FU was administered four times daily for 4 weeks (one course). Clinical examination (biomicroscopy and photography) and morphological evaluation of conjunctival cytological specimens were used to monitor the efficacy of local chemotherapy, side effects, and recurrences.
RESULTS---All patients showed clinical regression of conjunctival carcinoma after topical 1% 5-FU treatment. Neoplastic conjunctiva was completely replaced by normal epithelium within 3 months. Mean follow up was 27 months. One patient needed two courses of local chemotherapy for recurrent disease. An acute transient toxic keratoconjunctivitis was observed in all treated cases; it was easily controlled with topical therapy. No long term side effects were found.
CONCLUSIONS---Topical 1% 5-FU is effective in the treatment of recurrent, incompletely excised, and selected untreated conjunctival squamous cell carcinomas. Topical 1% 5-FU has no major complications. This study suggests that topical conjunctival chemotherapy with 1% 5-FU may be useful, at least as adjunctive therapy, in the treatment of conjunctival squamous cell carcinoma.


© 2000 by British Journal of Ophthalmology



This article has been cited by other articles:


Home page
Arch OphthalmolHome page
C. L. Shields, H. Demirci, B. P. Marr, A. Masheyekhi, M. Materin, and J. A. Shields
Chemoreduction With Topical Mitomycin C Prior to Resection of Extensive Squamous Cell Carcinoma of the Conjunctiva
Arch Ophthalmol, January 1, 2005; 123(1): 109 - 113.
[Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
P. A McKelvie, M. Daniell, A. McNab, M. Loughnan, and J. D Santamaria
Squamous cell carcinoma of the conjunctiva: a series of 26 cases
Br. J. Ophthalmol., February 1, 2002; 86(2): 168 - 173.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 by the BMJ Publishing Group Ltd.